JPWO2019241461A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019241461A5 JPWO2019241461A5 JP2020569778A JP2020569778A JPWO2019241461A5 JP WO2019241461 A5 JPWO2019241461 A5 JP WO2019241461A5 JP 2020569778 A JP2020569778 A JP 2020569778A JP 2020569778 A JP2020569778 A JP 2020569778A JP WO2019241461 A5 JPWO2019241461 A5 JP WO2019241461A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- conditions
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000002440 hepatic effect Effects 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- -1 pyridadinyl Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 210000001635 urinary tract Anatomy 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010054793 Arterial fibrosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010060774 Chondrosis Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 201000002327 urinary tract obstruction Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685395P | 2018-06-15 | 2018-06-15 | |
| US62/685,395 | 2018-06-15 | ||
| US201962831867P | 2019-04-10 | 2019-04-10 | |
| US62/831,867 | 2019-04-10 | ||
| PCT/US2019/036877 WO2019241461A1 (en) | 2018-06-15 | 2019-06-13 | Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527102A JP2021527102A (ja) | 2021-10-11 |
| JP2021527102A5 JP2021527102A5 (https=) | 2022-01-14 |
| JPWO2019241461A5 true JPWO2019241461A5 (https=) | 2022-01-14 |
| JP7190513B2 JP7190513B2 (ja) | 2022-12-15 |
Family
ID=67297250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569778A Active JP7190513B2 (ja) | 2018-06-15 | 2019-06-13 | ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11970511B2 (https=) |
| EP (1) | EP3807290B1 (https=) |
| JP (1) | JP7190513B2 (https=) |
| KR (1) | KR102802503B1 (https=) |
| CN (1) | CN112292386B (https=) |
| ES (1) | ES2912499T3 (https=) |
| WO (1) | WO2019241461A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113366007A (zh) * | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| JP2022508719A (ja) * | 2018-10-15 | 2022-01-19 | ガレクト バイオテック エービー | ガレクチンのガラクトシド阻害剤のプロドラッグ |
| KR20230006547A (ko) * | 2020-05-05 | 2023-01-10 | 브리스톨-마이어스 스큅 컴퍼니 | 갈렉틴-3의 소분자 억제제 |
| EP4157833A1 (en) | 2020-05-28 | 2023-04-05 | Bristol-Myers Squibb Company | Galectin-3 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| CN102439021B (zh) * | 2009-04-28 | 2015-09-02 | 格莱克特生物技术公司 | 半乳凝素的新型半乳糖苷抑制剂 |
| US20140243302A1 (en) | 2011-06-27 | 2014-08-28 | Merck Sharp & Dohme Corporation | Bridged bicyclic compounds for the treatment of bacterial infections |
| US9021050B2 (en) | 2012-08-31 | 2015-04-28 | Yume, Inc. | Network service system and method with off-heap caching |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) * | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| WO2014078655A1 (en) | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| EP3415522A1 (en) * | 2014-07-09 | 2018-12-19 | Galecto Biotech AB | Novel hybrid galactoside inhibitor of galectins |
| JP6904906B2 (ja) | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| ES2921500T3 (es) | 2015-11-09 | 2022-08-26 | Galecto Biotech Ab | 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas |
| JP6844991B2 (ja) | 2015-11-10 | 2021-03-17 | サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． | ジッパーを有する伸縮性衣類の製法 |
-
2019
- 2019-06-13 JP JP2020569778A patent/JP7190513B2/ja active Active
- 2019-06-13 CN CN201980039715.9A patent/CN112292386B/zh active Active
- 2019-06-13 WO PCT/US2019/036877 patent/WO2019241461A1/en not_active Ceased
- 2019-06-13 EP EP19740100.3A patent/EP3807290B1/en active Active
- 2019-06-13 ES ES19740100T patent/ES2912499T3/es active Active
- 2019-06-13 KR KR1020217000905A patent/KR102802503B1/ko active Active
- 2019-06-13 US US17/251,964 patent/US11970511B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527102A5 (https=) | ||
| JP6294277B2 (ja) | Ｈｅｃ１活性の調節因子およびそのための方法 | |
| JP7611278B2 (ja) | 金属酵素阻害剤化合物 | |
| JP2020510664A5 (https=) | ||
| JP2005509024A5 (https=) | ||
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| JP2014532070A5 (https=) | ||
| JP2012504141A5 (https=) | ||
| EP3793995B1 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| RU2007146798A (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2019131544A5 (https=) | ||
| JP2004511469A5 (https=) | ||
| JP2006513221A5 (https=) | ||
| CA2796826A1 (en) | Bifunctional quinoline derivatives | |
| JP2020532551A5 (https=) | ||
| JPWO2019241461A5 (https=) | ||
| IL305455A (en) | Aromatic compound, method of its preparation and use | |
| JP2017536342A5 (https=) | ||
| JPWO2019126085A5 (https=) | ||
| JPWO2020210308A5 (https=) | ||
| WO2007002637B1 (en) | N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| JP2009501745A5 (https=) | ||
| JP2007519633A5 (https=) | ||
| RU2017145086A (ru) | Производные 3-(6-хлор-3-оксо-3,4-дигидро-(2h)-1,4-бензоксазин-4-ил)пропионовой кислоты и их применение в качестве ингибиторов kmo | |
| JPWO2020198266A5 (https=) |